Thrombolytic Agents for Intravascular Clots - US12599653B2
Summary
The USPTO granted Patent US12599653B2 to Jinis Co., Ltd. for a thrombolytic agent comprising a dual-domain polypeptide with a thrombo-recognition domain and a thrombolytic domain effective for dissolving intravascular thrombus. The patent covers a pharmaceutical composition designed to prevent and treat thrombosis with reduced bleeding side effects compared to conventional thrombolytic therapies. The patent application was filed October 19, 2020, under Application No. 17770795.
What changed
The USPTO issued Patent US12599653B2 granting Jinis Co., Ltd. exclusive rights to a thrombolytic agent comprising a polypeptide with a thrombo-recognition domain (SEQ ID NO: 3 or 4) and a thrombolytic domain (SEQ ID NO: 1 or 2) for dissolving intravascular thrombus. The patent covers the pharmaceutical composition and methods of use for preventing and treating thrombosis with minimized bleeding side effects.
For pharmaceutical manufacturers and biotechnology companies developing thrombolytic therapies, this patent establishes protected intellectual property that may require design-around efforts or licensing negotiations. The dual-domain approach combining thrombus recognition with thrombolytic activity represents a potentially differentiated mechanism in the thrombosis treatment landscape.
What to do next
- Monitor for potential licensing opportunities
- Review patent claims for design-around considerations
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Thrombolytic agents for intravascular clots
Grant US12599653B2 Kind: B2 Apr 14, 2026
Assignee
JINIS CO., LTD.
Inventors
Seong Tshool Hong, Hyeon Jin Kim, Mdmehedi Hassan
Abstract
Provided is a thrombolytic agent for ‘intravascular thrombus’, and more particularly, to a thrombolytic agent having a thrombo-recognition domain and a thrombolytic domain. It also relates to a polypeptide for thrombolysis of an intravascular thrombus, a gene for that polypeptide, and a pharmaceutical composition containing the same. The polypeptide that recognizes ‘intravascular thrombus’ and dissolves thrombus of the present invention is characterized in that it consists of a thrombolytic domain comprising the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 and a thrombo-recognition domain comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 4. According to the present invention, the polypeptide for dissolving thrombus by recognizing ‘intravascular thrombus’ dissolves thrombus in the blood of a mammal without serious bleeding side effects has a preventive and therapeutic effect on thrombosis, thus preventing thrombosis and related diseases.
CPC Classifications
A61K 38/484 A61K 38/482 A61P 7/02 C12N 9/50 C12Y 304/21073 C12Y 304/21 C12Y 304/21068
Filing Date
2020-10-19
Application No.
17770795
Claims
1
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.